Compare Ross Stores, Inc. (ROST) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Ross Stores, Inc. trades at $222.12 (market cap $71.94B), while Vertex Pharmaceuticals Incorporated trades at $510.07 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Ross Stores, Inc. pays a 0.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ROST | VRTX | |
|---|---|---|
Market Cap | $71.94B | $127.55B |
Volume | 2,002,519 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $557.96 |
52-Week Low | $147.71 | $407.37 |
Typical Hold Time | 48 Days | 120 Days |
Enterprise Value | $72.39B | $121.68B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.53, up 0.59% with strong fundamental performance including three consecutive earnings beats and robust profitability metrics. The stock shows bearish technical signals despite positive analyst sentiment, with 64% buy ratings and a $274.14 consensus price target representing 22% upside potential. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents compelling investment potential with strong earnings momentum and expanding profit margins, though technical weakness and competitive pressures warrant caution. The company's value-focused strategy and operational discipline support continued growth, while elevated valuation multiples and market volatility pose near-term risks for shareholders.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
